VTAK Announces Preliminary Second Quarter Record Revenue in Excess of $1 million
Catheter Precision, Inc. (VTAK) reported preliminary unaudited Q2 2026 revenues of $1.037 million for the quarter ended June 30, 2026. The MedTech segment rose 27% vs Q2 2025, while the Flyte Vision Jet segment increased 61% sequentially over Q1 2026 to $767,000. The company also cited over $400,000 in revenue for the first two weeks of July 2026.
How this was made
The 30-second read
Why it matters
The company’s preliminary Q2 2026 record revenue and disclosed segment growth provide a near-term catalyst for traders positioning ahead of the final quarter results, while the forward-looking and preliminary nature increases uncertainty.
Market read
Fresh preliminary revenue datapoints and early-July run-rate can drive short-term sentiment and positioning, but final results may differ.
What to watch
The aviation segment is tied to a private aviation business and fleet/pilot ramp; execution risk and timing of revenue recognition could swing the final reported results.
Background
VTAK (Catheter Precision) operates a MedTech segment focused on cardiac electrophysiology and an aviation segment (Flyte) using Cirrus Vision Jets via an FAA Part 135 carrier subsidiary.
Ticker impact
Catheter Precision (VTAK) reports preliminary unaudited Q2 2026 record revenues of $1.037M, including MedTech and Flyte Vision Jet contributions.
Likely near-term positive bias into the final Q2 print, with volatility risk due to preliminary estimates.
The article discloses fresh, time-sensitive financial datapoints (preliminary Q2 revenue and early-July revenue) plus segment growth, but explicitly warns figures may change before finalization and are not reviewed by auditors.
Market effects
Could modestly support sentiment toward small-cap medtech and niche aviation-adjacent revenue models, but no broader sector signal is provided.
No clear regional market linkage beyond the company’s Fort Mill, South Carolina base.
Limited global relevance; story is company-specific with no international regulatory or macro catalyst.
Counterpoint
Because the release is preliminary and unaudited, the market may discount it or fade the move if the final Q2 numbers come in lower.
Key entities
- public_companyCatheter Precision, Inc.
NYSE American-listed company issuing preliminary unaudited Q2 2026 record revenue and segment growth updates.
- business_segmentFlyte Vision Jet segment
Aviation segment contribution cited as $767,000 in Q2 2026 and up 61% sequentially over Q1 2026.
- business_segmentMedTech segment
Cardiac electrophysiology-focused segment cited as up 27% over Q2 2025.
